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ABSTRACT
Introduction Type 2 diabetes is characterized by 
considerable heterogeneity in its etiopathogenesis and 
clinical presentation. We aimed to identify clusters of 
type 2 diabetes in Asian Indians and to look at the clinical 
implications and outcomes of this clustering.
Research design and methods From a network of 50 
diabetes centers across nine states of India, we selected 
19 084 individuals with type 2 diabetes (aged 10–97 
years) with diabetes duration of less than 5 years at the 
time of first clinic visit and performed k- means clustering 
using the following variables: age at diagnosis, body 
mass index, waist circumference, glycated hemoglobin, 
serum triglycerides, serum high- density lipoprotein 
cholesterol and C peptide (fasting and stimulated). This 
was then validated in a national epidemiological data set of 
representative individuals from 15 states across India.
Results We identified four clusters of patients, differing in 
phenotypic characteristics as well as disease outcomes: 
cluster 1 (Severe Insulin Deficient Diabetes, SIDD), cluster 
2 (Insulin Resistant Obese Diabetes, IROD), cluster 3 
(Combined Insulin Resistant and Deficient Diabetes, CIRDD) 
and cluster 4 (Mild Age- Related Diabetes, MARD). While 
SIDD and MARD are similar to clusters reported in other 
populations, IROD and CIRDD are novel clusters. Cox 
proportional hazards showed that SIDD had the highest 
hazards for developing retinopathy, followed by CIRDD, 
while CIRDD had the highest hazards for kidney disease.
Conclusions Compared with previously reported 
clustering, we show two novel subgroups of type 2 
diabetes in the Asian Indian population with important 
implications for prognosis and management. The 
coexistence of insulin deficiency and insulin resistance 
seems to be peculiar to the Asian Indian population and 
is associated with an increased risk of microvascular 
complications.
BACKGROUND
Global estimates suggest that 463 million indi-
viduals have diabetes as of 2019 and that this 
number will increase to 700 million by 2045.1 
More than 90% of these individuals have type 
2 diabetes, a condition that is characterized 
by considerable heterogeneity in its etio-
pathogenesis and clinical presentation. This 
heterogeneity has significant implications on 
the treatment and prognosis of patients with 
this condition.
Significance of this study
What is already known about this subject?
 ► Recently five distinct ‘clusters’ of individuals with 
diabetes with significantly different characteristics 
have been identified in a Scandinavian population.
 ► The unique Asian Indian phenotype predisposes 
them to young- onset type 2 diabetes (T2D).
What are the new findings?
 ► For the first time in India (and South Asia), cluster-
ing was done on 19 084 individuals with T2D using 
eight clinically relevant variables (age at diagnosis, 
body mass index, waist circumference, glycated 
hemoglobin, triglycerides, high- density lipoprotein 
cholesterol, and C peptide fasting and stimulated).
 ► Four replicable clusters were identified, two of which 
were unique to the Asian Indian population.
 ► The novel cluster ‘Combined Insulin Resistant and 
Deficient Diabetes’ is of particular importance as it 
is characterized by difficult- to- control hyperglyce-
mia and increased hazards of kidney disease and 
retinopathy.
How might these results change the focus of 
research or clinical practice?
 ► Classifying Asian Indians with T2D into phenotypic 
clusters provides insights into the pathophysiologi-
cal processes driving diabetes in this ethnic group, 
which could help in predicting the risk of complica-
tions and in focusing attention to individuals with the 
highest risk of morbidity and mortality.
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Recently, distinct ‘clusters’ or subgroups of individuals 
with type 2 diabetes have been identified in a Scandina-
vian population of 8980 individuals, based on five param-
eters representing the clinical presentation as well as the 
presence of insulin resistance and beta- cell dysfunction.2 
These five subgroups have been termed severe autoim-
mune diabetes, severe insulin deficient diabetes, severe 
insulin resistant diabetes, mild obesity- related diabetes 
and mild age- related diabetes. Further analyses of these 
subgroups have shown that such clustering might have 
implications with respect to the risk of diabetes compli-
cations as well as selection of the most appropriate treat-
ment. However, as the above study has been performed 
on a white Caucasian population, there is still no clarity 
on whether this classification is applicable to individuals 
with diabetes belonging to other ethnic groups.
Asian Indians (South Asians) represent an ethnic group 
with high predilection for developing type 2 diabetes; 
indeed, some of the largest increases in diabetes preva-
lence have been reported from the South Asian region. 
Type 2 diabetes in Asian Indians differs from that in white 
Caucasians in a number of significant ways. They tend to 
develop diabetes at a younger age and at lower levels of 
obesity than do white Caucasians. They also tend to prog-
ress faster from stages of ‘pre- diabetes’ to frank diabetes 
than members of other ethnic groups. The ‘Asian Indian 
phenotype’, characterized by high levels of abdominal 
fat and increased insulin resistance even at low levels of 
body mass index (BMI), has been postulated as a reason 
for this increased propensity to develop type 2 diabetes.3 
However, recent studies suggest that beta- cell dysfunction 
occurs quite early and rapidly in Asian Indians.4 Type 2 
diabetes in Asian Indians therefore appears to have a 
slightly different pathophysiology, with severe insulin 
deficiency being the primary defect in contrast to white 
Caucasians, in whom the main driver of diabetes is obesity 
and consequent insulin resistance.
It is therefore possible due to the above and the well- 
known younger age at diagnosis that clusters of type 2 
diabetes identified in Asian Indians based on parame-
ters used in the Western population might not behave 
exactly in the same manner with respect to treatment 
outcomes and risk of complications. In this paper, we 
attempt to identify distinct clusters of type 2 diabetes 
in Asian Indians and to look at the clinical implications 
and outcomes of this clustering. This study is part of the 
INdia- Scotland Partnership for pRecision mEdicine in 
Diabetes (INSPIRED) project.
RESEARCH DESIGN AND METHODS
Study population
Data for this analysis were obtained from the electronic 
medical records of a tertiary care center for diabetes, 
which has 50 branches spread across nine states of India. 
Clinical data of more than 400 000 patients have been 
captured and stored in the common diabetes electronic 
medical records (DEMR) system of the center,5 which 
represents one of the largest databases of patients with 
diabetes in the world. Each patient is provided a unique 
identification number at the time of their first regis-
tration, and clinical, anthropometric and biochemical 
data are updated in the system at each subsequent visit. 
Patients undergo a comprehensive evaluation for classifi-
cation of diabetes, assessment of control and presence of 
chronic complications at the time of their index visit, and 
these tests are repeated subsequently at regular intervals 
based on prespecified protocols.
The following examinations and investigations are 
performed for every patient during their clinic visits. 
Height, weight and waist circumference are measured 
using standardized techniques and the BMI calculated as 
weight (in kilograms) divided by the square of height (in 
meters). Blood pressure is recorded to the nearest 2 mm 
Hg from the right arm in a sitting position with a mercury 
sphygmomanometer (Diamond Deluxe BP Apparatus, 
Pune, India).
Blood samples are collected for the measurement of 
various parameters including fasting and postprandial 
plasma glucose, lipid profile, kidney and liver function 
tests, glycated hemoglobin (HbA1c), and C peptide 
(fasting and stimulated), while Glutamic Acid Decarbox-
ylase (GAD) autoantibodies are measured in a selected 
subset of patients. Fasting plasma glucose (FPG), serum 
cholesterol, serum triglycerides and high- density lipopro-
tein (HDL) cholesterol are measured using Hitachi 912 
Autoanalyzer (Hitachi, Mannheim, Germany). Fasting C 
peptide levels and stimulated (postbreakfast) C peptide 
levels are estimated by the electrochemiluminescence 
method on an Elecsys 2010 machine (Hitachi). To obtain 
the C peptide values, a fasting blood sample is obtained 
after an overnight fast of at least 8 hours and a postpran-
dial sample after 90 min of a standard South Indian 
breakfast (above 250 calories).6 HbA1c is measured by 
high- performance liquid chromatography using the 
Variant machine (Bio- Rad, Hercules, California, USA).
Diabetes is diagnosed if the FPG level is ≥126 mg/dL 
(7.0 mmol/L) and/or 2- hour postload glucose level is 
≥200 mg/dL (11.1 mmol/L) and/or if the patient has 
been prescribed pharmacotherapy for diabetes by a 
physician.7
Type 2 diabetes is diagnosed by absence of ketosis, good 
beta- cell reserve as shown by fasting C peptide assay 
>0.6 pmol/mL, absence of pancreatic calculi (on abdom-
inal radiograph), and response to oral hypoglycemic 
agents for at least 2 years.8
Assessment of complications is done as follows:
Retinopathy
A detailed retinal (fundus) examination is done by both 
direct and indirect ophthalmoscopy by a retinal specialist. 
Fundus photography is done using four- field stereo color 
retinal photography (Model FF 450 plus camera, Carl 
Zeiss, Jena, Switzerland). An Early Treatment Diabetic 
Retinopathy Study grading system that has been modified 
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and standardized in other population- based studies is 
used for the diagnosis of retinopathy.9 10
Nephropathy
Microalbuminuria is diagnosed if the albumin excretion 
was between 30 and 299 µg/mg and macroalbuminuria 
if albumin excretion is ≥300 µg/mg.11 Nephropathy is 
defined as the presence of either microalbuminuria or 
macroalbuminuria.
Chronic kidney disease (CKD) is defined as an esti-
mated glomerular filtration rate of less than 60 mL/
min/1.73m2 as calculated by the CKD- Epi formula.
Diabetic kidney disease is defined as the presence of 
CKD and/or albuminuria.
Homeostasis Model Assessment of beta- cell func-
tion (HOMA- B) and insulin resistance (HOMA- IR) are 
assessed based on C peptide concentrations and plasma 
glucose using the HOMA calculator (University of 
Oxford, Oxford, UK).12
From the DEMR, we selected 373 000 individuals aged 
10–97 years who had a diagnosis of type 2 diabetes. 
From these, we further selected 55 429 individuals who 
had baseline data available for the variables of interest, 
namely age at diagnosis, BMI, waist circumference, 
HbA1c, serum triglycerides, serum HDL cholesterol, and 
C peptide (fasting and stimulated). Of these, we selected 
20 850 individuals with reported duration of diabetes less 
than 5 years at first clinic visit (mean 1.74±1.4 years). After 
merging the HOMA- B and HOMA- IR and removing indi-
viduals with HOMA- B >500 and HOMA- IR <20 (n=1512), 
removing outliers for the remaining variables by the 5SD 
method (n=188) and excluding individuals who had a 
positive test for GAD autoantibodies (n=66), we had a 
final sample size of 19 084.
Cluster analysis
The k- means clustering method was done with k value 
of 4 using k- means function (max iteration=10 000) in 
R V.3.6.0. Cluster forming tendency of the data was vali-
dated by the Hopkins statistic value. The optimal number 
of clusters was determined based on silhouette width. 
Cluster- wise stability was computed by Jaccard bootstrap 
method through resampling of the data set 2000 times. 
A stable cluster generally yields Jaccard similarity index 
of greater than 0.75.13 Cluster analysis was performed on 
scaled and centered values. Cluster labels were assigned 
based on the phenotype characteristics of individual 
cluster mean values of the variables.
Sensitivity analysis was done using three time periods for 
duration of diabetes <1 year, <3 years, and <5 years. Clus-
tering tendency of the three different baseline diabetes 
duration data was found to have Hopkins statistic values 
of 0.19, 0.18, and 0.16, indicating that there were no 
significant differences in the cluster groups. Reclustering 
was done on men and women separately to validate the 
clustering and avoid the sex- dependent stratification 
effect on the phenotype variables. The minimum silhou-
ette width was similar in both genders (male and female).
Statistical models
The risk of development of diabetes complications was 
calculated using Cox regression models with covariate 
as a cluster label and adjusted for age at diagnosis and 
sex, after excluding individuals who already had compli-
cations at their first visit to the clinic. Cluster- wise time 
to reaching target goal was analyzed by Cox regression 
model. Cox proportional hazards assumptions were 
tested using R V.3.6.0.
Validation of clustering in a nationally representative 
epidemiological data set (ICMR-INDIAB study)
In order to validate the applicability of this clinic- based 
clustering to the general population, we attempted 
to replicate the clustering in the data set derived from 
the nationally representative Indian Council of Medical 
Research- India Diabetes (ICMR- INDIAB) study. ICMR- 
INDIAB is a nationwide population- based study on 
diabetes and related non- communicable diseases being 
carried out in all 29 states and 2 of the Union Territories 
of India based on a representative sample of each state. 
The detailed methodology of ICMR- INDIAB has been 
published elsewhere.14 Data from ICMR- INDIAB on the 
prevalence of diabetes in 15 states of India have been 
published.15
For purposes of this validation study, we selected 
3851 individuals with type 2 diabetes from the INDIAB 
study population in 15 states of India and clustering 
was performed using the following six variables: age at 
diagnosis, BMI, waist circumference, HbA1c, serum 
triglycerides and serum HDL cholesterol. We excluded C 
peptide from the analysis as we did not have data on this 
variable in the population- based sample. After excluding 
1521 individuals who did not have data on all our vari-
ables of interest as well as 88 outliers (5SD), we had a 
final sample size of 2204 individuals for the analysis. The 
k- means clustering was applied with k value as 4 (max iter-
ation=10 000) in R V.3.6.0. The optimal cluster number 
was determined based on the silhouette width method.
Comparison with the Scandinavian clusters
Using the same five variables (age at onset, BMI, HbA1c, 
HOMA- B and HOMA- IR) reported by Ahlqvist et al,2 
we then attempted to assess whether the clusters iden-
tified in the Scandinavian population are replicable in 
the DEMR- derived Asian Indian clinic population. We 
applied the k- means clustering (k=4) on the Asian Indian 
population (N=19 084) based on these five variables and 
analyzed the optimal cluster number based on the silhou-
ette width method.
We were unable to perform the Scandinavian clus-
tering in the population- based INDIAB sample as we did 
not have information on variables such as HOMA- B and 
HOMA- IR in the epidemiological data set.
RESULTS
Using cluster analysis based on eight clinically relevant 
variables (age at diagnosis, BMI, waist circumference, 
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HbA1c, serum triglycerides, serum HDL cholesterol, and 
C peptide fasting and stimulated), we were able to iden-
tify four replicable clusters of patients with type 2 diabetes 
in this Asian Indian population. The optimal number of 
clusters was based on silhouette width obtained from 
both the DEMR and the national ICMR- INDIAB data sets 
(online supplementary figure S1A,B). Table 1 shows the 
clinical and biochemical characteristics of these four clus-
ters with respect to the eight variables used for clustering 
and compares other clinically relevant variables across 
these clusters. The Jaccard similarity index was greater 
than 0.75, which confirmed that the cluster allocations 
were stable.
Cluster 1, referred to as Severe Insulin Deficient Diabetes 
(SIDD), included 26.2% of clustered patients and was 
characterized by the lowest BMI and waist circumference, 
as well as the lowest C peptide (fasting and stimulated) 
levels. HOMA- B and HOMA- IR were both low in this 
cluster. These individuals had the highest HbA1c values 
and were more likely to be using insulin compared with 
the other clusters.
Cluster 2 is a novel cluster which we refer to as Insulin 
Resistant Obese Diabetes (IROD). This comprised 
25.9% of clustered patients. These individuals had the 
highest BMI and waist circumference and the highest 
C peptide levels. HOMA- B and HOMA- IR were also the 
highest for this cluster. Metabolic control was inter-
mediate and individuals were more likely to be on 
metformin.
Cluster 3, another novel group identified in this popu-
lation, is referred to asCombined Insulin Resistant and 
Deficient Diabetes (CIRDD) and constitutes 12.1% of the 
study population. This group was characterized by the 
lowest age at onset. BMI and waist circumference were 
intermediate between SIDD and IROD. CIRDD had the 
highest triglyceride and lowest HDL cholesterol levels 
of all the four groups. C peptide levels were higher than 
SIDD, but lower than IROD. HOMA- B and HOMA- IR 
values were also intermediate between SIDD and IROD, 
indicating coexistence of insulin deficiency and insulin 
resistance. Metabolic control tended to be poor; however, 
only 15% were on insulin.
Table 1 Clinical and biochemical characteristics of the various subgroups of type 2 diabetes
Cluster 1 (SIDD) Cluster 2 (IROD) Cluster 3 (CIRDD) Cluster 4 (MARD)
n 5009 4934 2313 6828
Frequency, % 26.2 25.9 12.1 35.8
Men, % 65.8 59.8 73.7 58.6
Age at diagnosis, years 42.5 (10.8) 46.5 (10.4) 42.1 (9.8) 50.2 (10.3)
BMI, kg/m2 24.9 (3.5) 32.6 (4.1) 26.5 (3.1) 25.9 (2.9)
Waist circumference, cm 90 (8.8) 108 (8.9) 94.9 (8.1) 92.4 (7.4)
Glycated hemoglobin, % 10.7 (2.1) 8.3 (1.8) 9.1 (1.9) 7.2 (1.2)
Glycated hemoglobin, mmol/mol 93.0 67.0 76.0 55.0
Serum triglycerides, mg/dL 149 (59) 155 (59) 351 (102) 136 (50)
HDL cholesterol, mg/dL 40 (9) 38 (8) 36 (8) 42 (9)
C peptide fasting, pmol/mL 0.8 (0.3) 1.5 (0.4) 1.2 (0.4) 1.1 (0.3)
C peptide stimulated, pmol/mL 1.7 (0.6) 3.3 (0.8) 2.6 (0.8) 3 (0.7)
HOMA- B 38.8 (26.9) 100.8 (51.5) 64.5 (37.7) 94.1 (43.1)
HOMA- IR 2.8 (1.6) 4.1 (1.5) 3.8 (1.9) 2.6 (0.8)
WHR 0.93 (0.06) 0.97 (0.08) 0.96 (0.06) 0.94 (0.07)
Systolic blood pressure, mm Hg 123 (16) 128 (16) 127 (17) 127 (17)
Diastolic blood pressure, mm Hg 79 (9) 82 (9) 81 (10) 79 (9)
Serum cholesterol, mg/dL 188 (43) 176 (40) 206 (44) 177 (41)
LDL cholesterol, mg/dL 118 (37) 107 (35) 106 (38) 108 (35)
Insulin at registration, % 24.9 10.6 15.0 5.3
Metformin at registration, % 38.4 71.3 50.9 63.4
Sulfonylureas at registration, % 32.8 44.1 38.0 39.7
Statin at registration, % 30.2 37.8 37.3 37.8
ACE inhibitor at registration, % 2.4 3.5 2.9 3.4
Variables in bold are those used for clustering.
ACE, angiotensin converting enzyme; BMI, body mass index; CIRDD, Combined Insulin Resistant and Deficient Diabetes; HDL, high- 
density lipoprotein; HOMA- B, homeostasis model assessment of beta- cell function; HOMA- IR, homeostasis model assessment of 
insulin resistence; IROD, Insulin Resistant Obese Diabetes; LDL, low- density lipoprotein; MARD, Mild Age- Related Diabetes; SIDD, 
Severe Insulin Deficient Diabetes; WHR, waist hip ratio.
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Cluster 4, referred to as Mild Age- Related Diabetes 
(MARD), represented the most frequent cluster in this 
population (35.8%) and was characterized by later age 
at onset than other clusters. They were characterized by 
the highest HDL cholesterol, fairly preserved C peptide 
values and the best metabolic control of all the four 
groups. This group had the least use of insulin.
The characteristics of the clusters did not differ when 
split by gender (online supplementary table S1, online 
supplementary figure S2A,B) and duration of diabetes 
(online supplementary table S2).
Online supplementary table S3 shows the clustering 
without including HbA1c in the model. It was observed 
that the cluster characteristics are similar even without 
including HbA1c. In this model, SIDD was the most 
frequent cluster (32.7%), followed by MARD (31.9%), 
IROD (21.9%) and CIRDD (13.5%).
Table 2 shows the Cox proportional HR for various 
microvascular complications of diabetes among the clus-
ters. SIDD had the highest hazards for developing reti-
nopathy, followed by CIRDD (p<0.05), while CIRDD 
had the highest hazards for kidney disease (both CKD 
(p<0.05) and proteinuria) after adjusting for age, gender, 
HbA1c and blood pressure.
Figure 1 shows the time to reach treatment goal (HbA1c 
<7% (53 mmol/mol)) for various clusters. MARD showed 
the shortest time to reach goal, and CIRDD and SIDD the 
longest (online supplementary table S4).
Results from the validation with INDIAB data
Results from the validation study with the INDIAB data 
show that the clusters identified in the clinic population 
are replicable in this nationally representative data set 
(table 3).
In the INDIAB population, MARD was the most 
frequent cluster (34.8%), followed by IROD (30.3%), 
SIDD (24.7%) and CIRDD (7.6%). SIDD had the lowest 
BMI and waist circumference and highest HbA1c. 
IROD had the highest BMI and waist circumference 
Table 2 Cox HR for microvascular complications across clusters
Labels Events (%) HR (95% CI)* P value
Retinopathy SIDD 4.9 1.56 (1.22 to 1.98) <0.001
IROD 2.7 0.99 (0.79 to 1.24) 0.95
CIRDD 4.1 1.31 (1.01 to 1.71) <0.05
MARD 2.9 1 –
Nephropathy SIDD 6.4 1.18 (0.96 to 1.45) 0.1094
IROD 6.3 1.03 (0.87 to 1.23) 0.672
CIRDD 6.2 1.23 (1.05 to 1.46) <0.0001
MARD 5.7 1 –
CKD SIDD 1.5 1.30 (0.94 to 1.78) 0.1031
IROD 1.8 1.48 (1.12 to 1.97) <0.001
CIRDD 2.2 2.30 (1.61 to 3.26) <0.001
MARD 2 1 –
DKD SIDD 6 1.03 (0.88 to 1.20) 0.7002
IROD 6.3 1.20 (0.98 to 1.47) 0.0732
CIRDD 5.7 1.22 (1.03 to 1.45) <0.05
MARD 5.9 1 –
The bold values denote the differences that have attained statistical significance.
*Adjusted for age, sex, HbA1c and blood pressure, using MARD as the reference group, HR=1.0.
CIRDD, Combined Insulin Resistant and Deficient Diabetes; CKD, chronic kidney disease; DKD, diabetic kidney disease; HbA1c, 
glycated hemoglobin; IROD, Insulin Resistant Obese Diabetes; MARD, Mild Age- Related Diabetes; SIDD, Severe Insulin Deficient 
Diabetes.
Figure 1 Reaching treatment goal (glycated hemoglobin 
<7% (53 mmol/mol)). CIRDD, Combined Insulin Resistant and 
Deficient Diabetes; IROD, Insulin Resistant Obese Diabetes; 
MARD, Mild Age- Related Diabetes; SIDD, Severe Insulin 
Deficient Diabetes.
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and intermediate metabolic control. Individuals in the 
CIRDD cluster had BMI intermediate between SIDD and 
IROD, the highest triglycerides and lowest HDL, and 
high HbA1c and diastolic blood pressure. MARD had 
the highest age at diagnosis, the highest HDL levels, the 
lowest diastolic blood pressure and the best metabolic 
control. In all these respects, the clusters derived from 
the ICMR- INDIAB population behaved similar to those 
derived from the DEMR.
Results of comparison with the Scandinavian clusters
We then undertook the clustering based on the five vari-
ables used by Ahlqvist et al.2 We found that there were 
considerable differences between the clusters obtained 
in the Scandinavian population and the Asian Indian 
population (online supplementary tables S5 and S6). 
The insulin deficient cluster in the Asian Indian popu-
lation was similar to SIDD in the Scandinavian popula-
tion, as was the mild age- related subgroup to MARD 
(although with a lower age); however, the severely insulin 
resistant group in our population was also characterized 
by poor beta- cell function and higher levels of obesity 
(unlike severe insulin resistant diabetes in the Scandina-
vian population), while the mild obesity- related diabetes 
cluster could not be clearly defined in our population.
CONCLUSIONS
In this analysis of around 20 000 individuals with type 2 
diabetes from South India, we were able to identify four 
clusters of patients, differing in phenotypic characteris-
tics as well as disease outcomes with respect to diabetes 
control and risk of complications. These findings repli-
cated in a population- based study in India across 15 
Indian states. Two of these subgroups (SIDD and MARD) 
correspond to the clusters identified by Ahlqvist et al2 in 
the Scandinavian populations,while the other two are 
novel subgroups (CIRDD and IROD) with certain unique 
phenotypic and biochemical characteristics.
One of these novel subgroups, which we have termed 
CIRDD, comprises a minority of patients with type 2 
diabetes in our population, but represents a more aggres-
sive phenotype in that the age of onset is lower and their 
metabolic control is almost as poor as those of the severe 
insulin deficient (SIDD) group. Also, they took almost 
as long as those in the SIDD cluster to reach treatment 
goals. It is likely that the presence of dual pathophysi-
ology renders these individuals at high risk of developing 
diabetes at younger ages and predisposes them to poorer 
glycemic control. These individuals also had the highest 
serum triglyceride levels among all the clusters, possibly 
on account of accelerated lipolysis, secondary to insulin 
resistance. The insulin deficiency in these individuals 
could, in part, be attributed to beta- cell damage due to 
lipotoxicity. Patients with CIRDD also had the highest 
hazards of developing kidney disease and the second 
highest hazards for retinopathy. More aggressive therapy 
with a combination of agents targeting multiple patho-
physiologies of type 2 diabetes may be indicated in these 
patients (perhaps as early as at the time of diagnosis) so as 
to help them develop a favorable ‘legacy effect’ and thus 
help prevent long- term complications. They also need to 
be screened more aggressively for complications, partic-
ularly nephropathy and retinopathy. All these of course 
have to be tested prospectively through well- planned 
randomized clinical trials.
Individuals with the second novel subgroup, IROD, had 
better metabolic control than either SIDD or CIRDD, 
implying that they have sufficient beta- cell function to at 
Table 3 Validation of cluster in nationally representative ICMR- INDIAB data (n=2204)
Cluster 1 (SIDD) Cluster 2 (IROD) Cluster 3 (CIRDD) Cluster 4 (MARD)
n 603 667 167 767
% 27.4 30.3 7.6 34.8
Men, % 54.6 52.0 63.5 57.5
Age at diagnosis, years 40.1 (9.8) 48.2 (9.6) 45.4 (10.2) 55.5 (9.8)
BMI, kg/m2 22.7 (3.1) 29.9 (3.6) 25 (2.9) 23.4 (2.8)
Waist circumference, cm 82.8 (9.2) 102.5 (8.0) 90.4 (8.9) 86.1 (8.9)
Glycated hemoglobin, % 10.0 (2.1) 7.9 (1.8) 9.0 (2.0) 6.7 (1.2)
Glycated hemoglobin, mmol/mol 86.0 63.0 75.0 50.0
Serum triglycerides, mg/dL 180.6 (84.0) 187.8 (82.3) 414.0 (48.3) 151.1 (72.8)
HDL cholesterol, mg/dL 40.9 (10.5) 37.3 (8.9) 31.6 (8.1) 39.0 (10.3)
Serum cholesterol, mg/dL 183.5 (47.8) 178.3 (41.1) 218.9 (56.6) 171.7 (42.0)
Systolic blood pressure, mm Hg 135.1 (21.3) 141.6 (23.4) 139.6 (21) 142.4 (24.1)
Diastolic blood pressure, mm Hg 82.6 (11.1) 83.7 (12.6) 86 (11.3) 82.2 (12.2)
Variables in bold are those used for clustering.
BMI, body mass index; CIRDD, Combined Insulin Resistant and Deficient Diabetes; HDL, high- density lipoprotein; ICMR- INDIAB, Indian 
Council of Medical Research- India Diabetes; IROD, Insulin Resistant Obese Diabetes; MARD, Mild Age- Related Diabetes; SIDD, Severe 
Insulin Deficient Diabetes.
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least partially compensate for the obesity- related insulin 
resistance. However, they also had high risk of devel-
oping kidney disease. The higher risk of kidney disease in 
the two insulin resistant phenotypes (CIRDD and IROD) 
can be explained by the association of insulin resistance 
with increased salt sensitivity, glomerular hypertension 
and hyperfiltration.16 The excess risk of kidney disease 
in CIRDD over and above that in IROD can likely be 
explained by the poorer glycemic control in the former, 
on account of concomitant insulin deficiency.
The SIDD phenotype is similar to that described by 
Ahlqvist et al2 and had the worst metabolic control and 
took the longest time to reach treatment goal among the 
four subgroups. Similar to the Scandinavian population, 
the risk of retinopathy was highest in this insulin deficient 
phenotype, underlying the pivotal role played by hyper-
glycemia secondary to insulin deficiency in the develop-
ment of this microvascular complication. Enabling timely 
attainment of glycemic goals in these individuals would 
require more intensive use of insulin therapy, patient 
education and adoption of technologies than has been 
the case thus far.
Individuals in the MARD subgroup formed the most 
frequent cluster in our population and behaved similar 
to the corresponding cluster in the Scandinavian popula-
tion. They had the best metabolic control and the lowest 
risk of complications of all the four subgroups. However, 
these individuals had a significantly lower age of onset of 
diabetes (50.2 years) compared with those in the Scandi-
navian MARD cluster (67.3 years). This is likely explained 
by the lower age of onset of diabetes in the Asian Indian 
population in general. We cannot be certain whether our 
patients with MARD will continue to exhibit features of 
a mild phenotype of diabetes for the remainder of their 
lifespan; regular follow- up and monitoring is therefore 
essential even in this seemingly benign subgroup of type 
2 diabetes.
Recent attempts to replicate the subclassification of type 
2 diabetes in the US and Chinese population applying 
similar variables to those applied in the Scandinavian 
population have suggested that this European- oriented 
classification is generalizable to other ethnic groups.17 
In contrast, when we adopted the same approach in 
our Asian Indian population, we found that two of the 
subgroups could not be defined as described by Ahlqvist 
et al.2 We postulate that our novel clustering approach 
(using variables that have been shown to be associated 
with the Asian Indian phenotype) will be more clinically 
relevant to our population. While we did use C peptide 
in our clustering in order to prove the existence of beta- 
cell deficiency, we were able to replicate the clusters even 
without the C peptide values. In resource- constrained 
settings, the use of C peptide may not be feasible. It is 
therefore gratifying that the model works even without 
C peptide, which would help to scale up the use of these 
clusters to smaller clinics in remote areas; however, the 
predictive accuracy will be slightly lower if this approach 
is used. Similarly, the cluster characteristics remained 
stable even if HbA1c was not used, but considering that 
the clinical accuracy is much improved when HbA1c is 
used, we prefer that HbA1c stays in the model. Moreover, 
HbA1c is now part of the standard of care for diabetes in 
India, as in the rest of the world.
The strengths of our study include the use of a very large 
database on diabetes and identification of clusters based 
on phenotypic variables appropriate to the Asian Indian 
phenotype. However, the study does have a few limitations. 
Our institution being a private, pay- for- service clinic, data 
on all the variables of interest were not available for every 
patient due to financial constraints. Similarly, as our insti-
tution is also a tertiary referral center for diabetes, only the 
more severe or advanced cases of diabetes tend to visit the 
clinic, and this could have introduced an element of bias 
into our results. Our results, however, show that these clus-
ters are replicable when applied to a nationally representa-
tive population derived from a large epidemiological study, 
suggesting that they are generalizable to the Asian Indian 
population with diabetes.
In conclusion, we show that type 2 diabetes in the Asian 
Indian population can be classified into four phenotypic 
clusters with important implications for prognosis and 
management. While two of these clusters correspond 
to those reported in the white Caucasian population, 
the other two are novel and unique to the Asian Indian 
population. Of the four clusters, CIRDD is of particular 
importance as it represents a more aggressive phenotype 
of type 2 diabetes characterized by difficult- to- control 
hyperglycemia and markedly increased hazards of kidney 
disease and retinopathy. We acknowledge that catego-
rizing patients into subtypes will have less power to predict 
complications than using the continuous data,18 but 
conceptually we believe it is important to recognize that 
patients in India differ phenotypically and this pheno-
typic variation impacts on their risk of complications. 
Risk prediction either based on allocation to subgroups 
or using the continuous traits in clinical practice will help 
physicians tailor their treatment strategies such that indi-
viduals receive the most appropriate therapy right from 
the time of diagnosis.
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